Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET. A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation. About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engine
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress [Yahoo! Finance]Yahoo! Finance
- Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressGlobeNewswire
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Wells Fargo & Company from $63.00 to $60.00. They now have an "overweight" rating on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Stifel Nicolaus from $72.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
ARVN
Earnings
- 5/7/24 - Beat
ARVN
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/17/24 - Form ARS
- ARVN's page on the SEC website